Cancer immunotherapy has revolutionized the field of oncology during the past decade. However, most of these breakthroughs have targeted advanced stage cancers with a limited number of patients who respond to immunotherapies. More new therapies are being developed and more combinations are being evaluated to treat patients who do not respond or stop responding to existing therapies. On the other side of intervention against cancer, prevention has had a tremendous impact on cancer incidence by targeting etiological factors such as tobacco use, HPV vaccine or promoting early screening. The field of cancer prevention is at a corner with the possibility of leveraging the immune-based therapies to target early-stage cancer or premalignant lesions. Better understanding of the continuum of cellular and molecular modifications which often occur through many decades offer an opportunity to develop new diagnostics and interventions. In particular understanding of the premalignant immune microenvironment and the mechanism of establishment of immune disfunction and exclusion could provide a rationale for the development of immunotherapies adapted to the premalignant lesions.
Some critical aspect related to immune-based prevention of cancer include:
• Identification of biomarkers for early detection of premalignant lesions
• Leverage the common viral etiology in cancer (HPV, EBV, polyomavirus).
• Characterization of the mutation burden in premalignant lesions
• Prophylactic/Therapeutic vaccines to target premalignant lesions
• Animal models for premalignant lesions
• Genetic and epigenetic alterations during early progression (colorectal cancer, Linch syndrome, microsatellite instability)
• Development of novel topical therapies for treatments of early lesions
In this Research Topic, we welcome Original Research articles, Reviews, Mini Reviews, Case Reports, Clinical Trials, Methods, and Perspectives that address the screening and interventions toward premalignant epithelial neoplasms.
We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). We hereby state publicly that the IUIS has had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of the IUIS.
Cancer immunotherapy has revolutionized the field of oncology during the past decade. However, most of these breakthroughs have targeted advanced stage cancers with a limited number of patients who respond to immunotherapies. More new therapies are being developed and more combinations are being evaluated to treat patients who do not respond or stop responding to existing therapies. On the other side of intervention against cancer, prevention has had a tremendous impact on cancer incidence by targeting etiological factors such as tobacco use, HPV vaccine or promoting early screening. The field of cancer prevention is at a corner with the possibility of leveraging the immune-based therapies to target early-stage cancer or premalignant lesions. Better understanding of the continuum of cellular and molecular modifications which often occur through many decades offer an opportunity to develop new diagnostics and interventions. In particular understanding of the premalignant immune microenvironment and the mechanism of establishment of immune disfunction and exclusion could provide a rationale for the development of immunotherapies adapted to the premalignant lesions.
Some critical aspect related to immune-based prevention of cancer include:
• Identification of biomarkers for early detection of premalignant lesions
• Leverage the common viral etiology in cancer (HPV, EBV, polyomavirus).
• Characterization of the mutation burden in premalignant lesions
• Prophylactic/Therapeutic vaccines to target premalignant lesions
• Animal models for premalignant lesions
• Genetic and epigenetic alterations during early progression (colorectal cancer, Linch syndrome, microsatellite instability)
• Development of novel topical therapies for treatments of early lesions
In this Research Topic, we welcome Original Research articles, Reviews, Mini Reviews, Case Reports, Clinical Trials, Methods, and Perspectives that address the screening and interventions toward premalignant epithelial neoplasms.
We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS). We hereby state publicly that the IUIS has had no editorial input in articles included in this Research Topic, thus ensuring that all aspects of this Research Topic are evaluated objectively, unbiased by any specific policy or opinion of the IUIS.
